Once a clinical trial is authorised under Regulation (EU) No 536/2014, almost any change a sponsor makes, such as a protocol amendment, a new site, an updated investigator's brochure or a revised IMP dossier, raises the same question: is this a substantial modification that needs prior authorisation? If the classification or routing is wrong, the sponsor can lose time on the statutory clock, receive requests for information, or have the application lapse. Any of these can delay recruitment, dosing or data readouts across several Member States.
The analysis below covers how the Clinical Trials Regulation defines a substantial modification and how Part I and Part II changes are submitted and assessed through CTIS. It also covers the roles of the reporting Member State and the Member States concerned, the timelines and decision steps that apply, and the procedural and substantive grounds on which modifications are commonly questioned or refused.
Substantial modifications under the EU Clinical Trials Regulation: definition, CTIS assessment and common grounds for questions or refusal
Under Regulation (EU) No 536/2014 (the Clinical Trials Regulation, CTR), a change to an authorised trial is a substantial modification (SM) if it is likely to have a substantial impact on subject safety or rights, or on the reliability and robustness of trial data. An SM cannot be implemented until it has been authorised through the EU portal (CTIS). Part I aspects are assessed jointly by a reporting Member State (RMS) on a fixed statutory clock. Part II aspects are assessed nationally. Each Member State concerned (MSC) then issues a single decision. A modification can fail in one of three ways. The application lapses on a procedural deadline. The sponsor routes or classifies the change incorrectly. Or a Member State raises one of the limited legal grounds for refusal, which include safety, data reliability, inferior treatment, national law, Part II non-compliance and a negative ethics committee opinion.
Key points
- Definition. An SM is "any change to any aspect of the clinical trial" made after a decision under Articles 8, 14, 19, 20 or 23 that is "likely to have a substantial impact on the safety or rights of the subjects or on the reliability and robustness of the data generated in the clinical trial" 2324.
- Prior authorisation is mandatory. An SM, "including the addition of a clinical trial site or the change of a principal investigator", may only be implemented once approved under Chapter III of the CTR 25.
- The sponsor classifies the change. The sponsor assesses each change case by case and is encouraged to contact the national contact point if in doubt 84.
- There are three categories of change: SM, non-substantial modification relevant to supervision (Article 81(9)), and other non-substantial modification (NSM) 270271.
- Statutory clocks are short and strict. A sponsor gets at most 12 days to answer a request for information (RFI). If it misses that deadline, the application lapses 89.
- Grounds for refusal are closed lists. An MSC can disagree with a favourable Part I conclusion only on the grounds listed in the Regulation 130.
What counts as a substantial modification
The legal test
The CTR defines an SM by its likely impact, not by the document that changes 2324. Commission guidance in EudraLex Volume 10 applies the same test. A change is substantial if it is likely to significantly affect subjects' safety or rights, or the reliability and robustness of trial data. The sponsor assesses this case by case 114. Two points from the guidance matter in practice:
- Including a non-substantial change in an SM application does not mean that change has been assessed or approved 84.
- Classification follows the effect of the change, not the document being updated. CTIS cannot tell apart different kinds of content change within one document, so the sponsor must pick the correct route 377.
Three categories of change
Annex IV of the CTR Questions and Answers ("Classification of changes to ongoing clinical trials") sorts changes into SM, 81.9NSM (non-substantial but relevant to supervision) and NSM (other non-substantial). Its examples are non-exhaustive 270271.
| Category | Examples from CTR Q&A Annex IV and related Volume 10 guidance |
|---|---|
| Substantial modification (SM) | Change of sponsor entity that also brings changes such as insurance or legal-representative changes, or addition of a sponsor or co-sponsor; change in the definition of end of trial; design changes such as removing an arm or adding an unforeseen period; inclusion/exclusion changes with significant impact; reduction in scheduled visits, including replacement with remote visits 272273. Adding an exclusion criterion because of potential liver toxicity described in the IB 115. A new IB version with changes affecting the trial's benefit-risk balance 118. Adding a clinical trial site 120387. Change of principal investigator 121. |
| Article 81(9) non-substantial (81.9NSM) | Sponsor name change with the same legal entity; change of sponsor or co-sponsor legal entity involving only administrative changes to trial documents; changes in co-sponsor responsibilities or sponsor contact details 272274. A significant increase in overall trial duration, provided IMP exposure is not extended and the end-of-trial definition does not change 273. An annual IB update with no significant change to subject safety or benefit-risk 118. |
| Other non-substantial (NSM) | Minor contact-detail changes that do not affect supervision; minor protocol clarifications; an increase in trial duration of less than 10%; a change in subjects per Member State where the absolute total is unchanged or the change is insignificant 272274273. |
Changes that affect both Part II informed consent and Part I should be submitted for both Parts 123. For an adaptive design, changes already described and specified in the latest authorised protocol can be implemented without a new SM, unless the assessing Member State requires one 116.
Quality and IMPD changes
Quality changes follow their own guidance tables. The 2022 CTR-aligned quality guidelines apply the same SM / Article 81(9) / NSM split and ask sponsors to classify changes case by case 198199200.
| Change | Typically substantial | Typically non-substantial |
|---|---|---|
| Manufacturer or site | Adding or replacing an IMP manufacturing, packaging, QC-testing or batch-release/QP-certification site 205206. A new drug-substance manufacturer 117. | Alternate manufacturing sites within one company with the same process and specifications (Article 81(9)) 117. Manufacturer name change; deleting a site for reasons unrelated to quality or safety 207. |
| Synthesis or process | A different route of synthesis 117217. Significant process or critical-control changes. For biologicals: a new expression cell line, adding or removing a purification step, changes affecting viral clearance, reprocessing not described in the IMPD 213214215. | Changes to parameters within the same process where no effect on product quality is shown or expected 216218. |
| Specifications | Widened acceptance criteria or deleted parameters; additions for safety or quality reasons; for biologicals, a new test method or a method change that affects performance 208209. | Tightened limits for reasons unrelated to safety or quality; improvements to the same analytical method with comparable or better results 210211. |
| Shelf life | Extension outside the approved stability protocol or without a prior commitment; changes to approved in-use stability recommendations for biologicals 201202. | Extension based on the approved protocol (chemical IMPs) 203. For biologicals, only within defined limits: no more than double, no more than 12 months beyond real-time data, and no significant trends or out-of-specification results 204. |
The guidance says not to send supporting documentation for quality NSMs separately. These changes should be folded into the next IMPD update or SM, with the substantial changes clearly identified 219220221.
When a change becomes a new trial
Some changes are too large to handle as an SM and need a new trial application. Volume 10 gives three examples: an unplanned new IMP, a change to the main objective or primary endpoint in any phase, and an unplanned and unjustified added arm or placebo group 119250. The sponsor makes this call case by case and should consult the national contact point if in doubt 251.
Handling non-substantial changes in CTIS
- Article 81(9) changes must be kept permanently updated in the EU database 156. CTIS uses a dedicated NSM route for them that must not contain other NSMs or SMs. Part I and Part II Article 81(9) updates must be made before submitting a Part I or Part I+II SM 373374.
- Other NSMs are not notified on their own. They are listed in the cover letter of the next SM that affects the same Part of the dossier. If that SM is rejected, the NSMs stay in the Trial Master File and go in with the next SM 375376.
- Using the NSM route does not mean approval. A standalone Article 81(9) submission may show as "authorised" in CTIS, but it is not assessed or approved. A change cannot use this route if it triggers changes that need an SM, and several Article 81(9) changes can together amount to an SM 118377378.
The application dossier (CTR Annex II)
Annex II ("Application dossier for substantial modification") requires 135136137138139:
- A cover letter identifying the trial, the applicant and the modification, highlighting special issues and information on risks to subjects, and listing affected trials where relevant.
- A completed modification application form.
- A description of the modification: extracts with the old and new wording, an extract with only the new wording, and an explanation. Where changes are extensive, a new version of the whole document with a table of amendments is acceptable. Each new version must carry a date and an updated version number.
- Supporting information where applicable. This includes at least data summaries and an updated overall risk/benefit assessment.
Adding a site requires the site-suitability documentation in Annex I.N.67 388. When an RFI response changes trial documents, both tracked and clean versions are expected 290.
How SMs are assessed and authorised through CTIS
The sponsor submits the dossier to the MSCs through the EU portal 145. The procedure depends on whether the change affects Part I (the jointly assessed aspects, such as protocol, IB and IMPD), Part II (national aspects), or both.
Part I modifications (Articles 17 to 19)
| Step | Statutory rule |
|---|---|
| Validation | The RMS is the one that handled the initial authorisation. Other MSCs may send considerations within 5 days. Within 6 days of submission, the RMS tells the sponsor whether the change concerns Part I and whether the dossier is complete. If it does not respond in time, both are deemed satisfied 146147. |
| Correction | If either requirement is not met, the sponsor gets up to 10 days to comment or complete the dossier, and the RMS then has 5 days to respond. If the sponsor does not respond, the application lapses in all MSCs 148. |
| Assessment | The RMS concludes that the modification is acceptable, acceptable with specified conditions, or not acceptable. It does this within 38 days of validation (the reporting date) and also considers whether the trial remains low-intervention 149. For multinational trials, Commission Q&A practice (not the Regulation text) splits the 38 days into a 19-day initial assessment, a 12-day coordinated review and a 7-day consolidation. A further 50 days can be added to consult experts on the products specified in the Regulation, such as ATMPs 150. |
| RFI | Only the RMS may request information. It can extend the reporting period by up to 31 days. The sponsor's deadline cannot exceed 12 days (statutory). Commission Q&A practice then allows a 12-day joint review and up to 7 days of consolidation within the 31-day extension. A missed deadline makes the application lapse in all MSCs 89. |
| Decision | Each MSC issues a single decision within 5 days of the reporting date: authorised, authorised with conditions, or refused. Conditions are limited to those that by their nature cannot be met at the time of authorisation 128129. If an MSC does not decide in time, the assessment report conclusion is deemed to be its decision 132. |
Adding up these statutory periods (this is arithmetic, not a figure stated in the Regulation): a complete Part I SM with no RFI takes about 49 days from submission to decision (6 + 38 + 5). An RFI can add up to 31 days.
Part II-only modifications (Article 20)
The MSC has 6 days to validate. A 10-day correction window and a 5-day reply period apply if needed. If the sponsor does not respond, the application lapses in that MSC 161162. The MSC sends Part II of the assessment report and one decision within 38 days of validation. A justified, territory-specific RFI can extend this by up to 31 days: the sponsor has at most 12 days to reply and the MSC at most 19 days to finish. If the MSC misses its decision deadline, the modification is deemed authorised 28163.
Modifications affecting Parts I and II (Articles 21 to 23)
Validation follows Article 17. Part I is assessed under Article 18. Each MSC assesses Part II for its own territory under Article 22, with the same 38-day period and RFI extensions 165167. Each MSC issues one decision within 5 days of the later of the Part I reporting date and the end of its Part II assessment 168. A combined application cannot be partly authorised. A permitted disagreement on Part I, non-compliance on Part II, or a qualifying negative ethics committee opinion leads to refusal of the whole application in that MSC. If the sponsor misses a Part II RFI deadline, the whole combined application lapses in that MSC, but Part I can still be authorised elsewhere 57.
Authorisation with conditions
Conditions must relate to matters raised during the assessment, typically in the RFI, so the sponsor has had a chance to respond. They must appear in the assessment report conclusion and the MSC decision, and they are available only while the trial's overall benefit-risk balance remains positive 61. Exceptionally, a sponsor may have to meet a condition before the trial starts or before the first subject is included 286287. Sponsors can fulfil conditions through the Article 81(9) route or an SM, unless the condition specifies an SM. Using the non-SM route for the wrong purpose can lead to corrective measures 288289.
Concurrency, withdrawal and multi-trial submissions
- A Part I+II SM cannot be submitted while another SM assessment is ongoing in any MSC, or while an application to add an MSC is ongoing. A Part II SM cannot overlap another Part II SM in the same MSC, but Part II assessments can run in parallel in different MSCs 85.
- If another change is needed during an ongoing assessment, the sponsor can wait, or withdraw the ongoing application and resubmit a combined one. Safety measures that cannot wait should be taken and notified, with the SM following once the ongoing SM is finalised 86.
- A single SM application can cover several trials when the same change applies to each of them in the same way. Each trial must already be authorised and have no assessment outstanding 87.
- Withdrawing a Part I (or Part I+II) SM applies to all MSCs. A Part II-only SM can be withdrawn from one or more MSCs 88.
Urgent safety measures and temporary halts
Sponsors and investigators may take urgent safety measures without prior authorisation. The sponsor must notify the MSCs within 7 days 154. That notification does not replace any SM needed to update the dossier 404405. If a safety-related temporary halt affects benefit-risk, the trial can only restart after an authorised SM 155406. If stopping and restarting criteria were pre-specified in the protocol, the sponsor can avoid both a temporary-halt notification and a restart SM 408409410.
Trials transitioned from Directive 2001/20/EC
If a transitioned trial cross-refers to a trial still under the Directive, that second trial should be transitioned before the first trial's first SM 228. If an IMPD referenced by a transitioned trial is not available in CTIS, an "IMPD-Q-only" submission may need to go with the first Part I SM after transition 229.
Why substantial modifications are questioned or refused
1. The closed legal grounds
A favourable Part I conclusion by the RMS is deemed to be each MSC's conclusion. An MSC may disagree only on three grounds:
- participation would give subjects treatment inferior to normal clinical practice in that Member State;
- the modification would infringe national law referred to in Article 90;
- subject-safety or data-reliability and robustness considerations raised during the assessment.
The MSC must send a detailed justification through the portal 13059. Refusal is also mandatory where an ethics committee issues a negative opinion valid for the whole Member State, and an appeal procedure must be available 131. For Part II, refusal requires duly justified non-compliance with Part II requirements or a qualifying negative ethics committee opinion 164169. If the RMS concludes that a Part I change is not acceptable, that conclusion applies to all MSCs 131.
2. Procedural lapse rather than substantive refusal
Many failed SMs lapse rather than being refused on the merits. This happens when:
- the sponsor does not complete an incomplete dossier within the correction window 148;
- the sponsor does not answer an RFI within the deadline, which is never more than 12 days. For Part I the application lapses in all MSCs; for Part II it lapses in that MSC 8990. For combined applications, a missed Part II RFI causes the whole application to lapse in that MSC 57.
Volume 10 guidance says that usually only one RFI round is feasible. RFIs should focus on critical issues whose resolution would allow authorisation, possibly with conditions, rather than rejection. Sponsors are expected to resolve those issues in their response 5491. The guidance adds that complete, high-quality initial applications help avoid rejections caused by time constraints 290. RAPS reported the same expectation of a single RFI and the 12-day ceiling in its coverage of the CTR Q&A 357.
3. Misclassification and route errors
- Routing an SM as a non-substantial change. Article 81(9) submissions are not assessed. Using that route for a change that triggers SM-level changes, or letting several Article 81(9) changes add up to an SM, can lead to corrective measures 377378289.
- Treating a new trial as an SM. Unplanned new IMPs, changes to the main objective or primary endpoint, or unjustified new arms or placebo groups call for a new trial application 250.
- Adding changes during the RFI phase. RAPS reported that sponsors are discouraged from adding non-substantial changes during an RFI phase unless the response requires them 358379.
- Overlapping submissions. The concurrency rules for Part I+II SMs mean a second application cannot be submitted while another SM is under assessment 85.
4. Weak justification or supporting data
Annex II requires data summaries and an updated overall risk/benefit assessment where applicable 139. Conditional authorisation requires a positive overall benefit-risk balance; without one, the application should be rejected 61359360.
Quality changes draw particular scrutiny:
- Significant manufacturing or formulation changes to biological IMPs need an appropriate comparability exercise and enough data to assess consequences for patient safety 318.
- EMA's ATMP guideline warns that substantial changes during pivotal studies can call into question whether data generated with pre-change material remain representative 319.
- A change to a previously applied biological active-substance specification must be indicated and justified 212.
- A draft EMA concept paper on revising the chemical IMP quality guideline notes that sponsors and assessors classify changes differently. It names synthesis descriptions, impurities, shelf-life extensions, in-use stability, non-standard manufacturing processes and specifications as areas that need clearer requirements 305.
5. Data limits and reform
The regulator and news sources reviewed do not publish SM refusal rates or a ranked list of common SM deficiencies. RAPS's early CTIS snapshot counted four SM applications among 195 CTIS applications 361. EMA has said that the proposed Biotech Act would give greater flexibility for major modifications to ongoing trials, described as a proposed change rather than current procedure 342343. Commission officials have also pointed to a future delegated act that could change authorisation procedures, including SMs, for combined studies; those proposals remain subject to negotiation 363364.